Psychedelic: Difference between revisions
>Unity Overhauled toxicity section; various miscellanea |
>Joedelisyd m added one lysergamide analogue for psychedelics group |
||
Line 1: | Line 1: | ||
[[File:Oversoul by Alex Grey.jpg|300px|thumb|right|''Oversoul'' by '''[http://alexgrey.com/art/paintings/soul/oversoul/ Alex Grey]''' - An example of [[psychedelic]] artwork created by the renowned visionary artist Alex Grey. This image is a representation of an experience report found in the 1901 book [http://en.wikipedia.org/wiki/Cosmic_Consciousness ''Cosmic Consciousness''] ]] | [[File:Oversoul by Alex Grey.jpg|300px|thumb|right|''Oversoul'' by '''[http://alexgrey.com/art/paintings/soul/oversoul/ Alex Grey]''' - An example of [[psychedelic]] artwork created by the renowned visionary artist Alex Grey. This image is a representation of an experience report found in the 1901 book [http://en.wikipedia.org/wiki/Cosmic_Consciousness ''Cosmic Consciousness''] ]] | ||
'''Psychedelics''' (also known as '''[[serotonergic]] [[hallucinogens]]''') are a class of [[psychoactive substances]] that produce an altered state of consciousness marked by unusual changes in perception, mood, and cognitive processes.<ref name="nicholsPSY>Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478</ref> While their precise mechanism of action is not known, psychedelics are thought to produce their characteristic effects by binding to [[serotonin]] [[receptors]] ('''5'''-'''h'''ydroxy'''t'''ryptamine or '''5-HT'''), particularly the 5-HT<sub>2a</sub> subtype. Serotonin plays a number of critical roles throughout the human body and is a key [[neurotransmitter]] involved in the functioning and regulation of sensory perception, behavior, mood, cognition and memory.<ref name=nichols5HT>Nichols, D. E., & Nichols, C. D. (2008). Serotonin Receptors. Chemical Reviews, 108(5), 1614-1641. https://doi.org/10.1021/cr078224o</ref> | '''Psychedelics''' (also known as '''[[serotonergic]] [[hallucinogens]]''') are a class of [[psychoactive substances]] that produce an altered state of consciousness marked by unusual changes in perception, mood, and cognitive processes.<ref name="nicholsPSY">Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478</ref> While their precise mechanism of action is not known, psychedelics are thought to produce their characteristic effects by binding to [[serotonin]] [[receptors]] ('''5'''-'''h'''ydroxy'''t'''ryptamine or '''5-HT'''), particularly the 5-HT<sub>2a</sub> subtype. Serotonin plays a number of critical roles throughout the human body and is a key [[neurotransmitter]] involved in the functioning and regulation of sensory perception, behavior, mood, cognition and memory.<ref name="nichols5HT">Nichols, D. E., & Nichols, C. D. (2008). Serotonin Receptors. Chemical Reviews, 108(5), 1614-1641. https://doi.org/10.1021/cr078224o</ref> | ||
Human usage of psychedelics predates written history, and there is growing evidence that they were employed by early cultures in a variety of sociocultural and ritual contexts.<ref name="nicholsPSY /> In modern times, psychedelic substances are used for a number of purposes that span from the traditional shamanic forms (such as the use of [[ayahuasca]] in the Amazon jungle, or [[peyote]] among Native Americans) to more modern forms of New Age spiritual, [[transpersonal]], or religious practices. Psychedelics, particularly those in the traditional or herbal forms, are sometimes referred to as [[entheogens]] (i.e. "generating the divine within")<ref>Dictionary - Entheogen | http://dictionary.reference.com/browse/entheogen</ref> by those who use them for these purposes, although they are also often used in purely [[recreational drug use|recreational settings]]. | Human usage of psychedelics predates written history, and there is growing evidence that they were employed by early cultures in a variety of sociocultural and ritual contexts.<ref name="nicholsPSY" /> In modern times, psychedelic substances are used for a number of purposes that span from the traditional shamanic forms (such as the use of [[ayahuasca]] in the Amazon jungle, or [[peyote]] among Native Americans) to more modern forms of New Age spiritual, [[transpersonal]], or religious practices. Psychedelics, particularly those in the traditional or herbal forms, are sometimes referred to as [[entheogens]] (i.e. "generating the divine within")<ref>Dictionary - Entheogen | http://dictionary.reference.com/browse/entheogen</ref> by those who use them for these purposes, although they are also often used in purely [[recreational drug use|recreational settings]]. | ||
[[Subjective effects]] can vary significantly depending on class, but generally include some form of [[geometry|open and closed-eye visuals]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[euphoria]], and [[ego loss]]. The so-called classical psychedelics, which consist of [[LSD]], [[psilocybin mushrooms]], [[mescaline]], and [[DMT]] ([[ayahuasca]]) are considered to produce the archetypal psychedelic effects and also have the most established safety profiles. Psychedelics can be divided into three major sub-classes: [[tryptamines]], [[lysergamides]], and [[phenethylamines]]. Psychedelic tryptamines are based on, or derive from, [[dimethyltryptamine]] (DMT), lyergamides on [[LSD]], and phenethylamines on [[mescaline]]. | [[Subjective effects]] can vary significantly depending on class, but generally include some form of [[geometry|open and closed-eye visuals]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[euphoria]], and [[ego loss]]. The so-called classical psychedelics, which consist of [[LSD]], [[psilocybin mushrooms]], [[mescaline]], and [[DMT]] ([[ayahuasca]]) are considered to produce the archetypal psychedelic effects and also have the most established safety profiles. Psychedelics can be divided into three major sub-classes: [[tryptamines]], [[lysergamides]], and [[phenethylamines]]. Psychedelic tryptamines are based on, or derive from, [[dimethyltryptamine]] (DMT), lyergamides on [[LSD]], and phenethylamines on [[mescaline]]. | ||
Unlike other highly prohibited substances, most psychedelics have not been shown to be physiologically toxic and none have been shown to be addictive.<ref name="nicholsPSY /> However, adverse psychological reactions such as severe [[anxiety]], [[paranoia]], [[delusions]], and [[psychosis]] are always possible, particularly for those predisposed to mental disorders.<ref>{{cite journal|last=Strassmann|first=Rick|title=Adverse reactions to psychedelic drugs. A review of the literature|journal=Journal of Nervous and Mental Disease|volume=172|issue=10|pages=577–595|doi=10.1097/00005053-198410000-00001|pmid=6384428|year=1984|issn=0022-3018|oclc=1754691}}</ref> As a result, it is highly advised to use [[Harm reduction#Hallucinogens|harm reduction practices]] if using these substances. | Unlike other highly prohibited substances, most psychedelics have not been shown to be physiologically toxic and none have been shown to be addictive.<ref name="nicholsPSY" /> However, adverse psychological reactions such as severe [[anxiety]], [[paranoia]], [[delusions]], and [[psychosis]] are always possible, particularly for those predisposed to mental disorders.<ref>{{cite journal|last=Strassmann|first=Rick|title=Adverse reactions to psychedelic drugs. A review of the literature|journal=Journal of Nervous and Mental Disease|volume=172|issue=10|pages=577–595|doi=10.1097/00005053-198410000-00001|pmid=6384428|year=1984|issn=0022-3018|oclc=1754691}}</ref> As a result, it is highly advised to use [[Harm reduction#Hallucinogens|harm reduction practices]] if using these substances. | ||
==Etymology== | ==Etymology== | ||
Line 41: | Line 41: | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
<div class= | <div class="flex-panel"> | ||
<div class= | <div class="flex-column"> | ||
<div class="panel radius"> | <div class="panel radius"> | ||
<h3 class="panel-header">[[Visual effects - Psychedelics|Visual effects]] [[File:Eye.svg|x20px|right|link=]]</h3> | <h3 class="panel-header">[[Visual effects - Psychedelics|Visual effects]] [[File:Eye.svg|x20px|right|link=]]</h3> | ||
Line 64: | Line 64: | ||
*[[Diffraction]] | *[[Diffraction]] | ||
*[[Drifting]] | *[[Drifting]] | ||
** [[Drifting#Morphing|Morphing]] | **[[Drifting#Morphing|Morphing]] | ||
** [[Drifting#Breathing|Breathing]] | **[[Drifting#Breathing|Breathing]] | ||
** [[Drifting#Melting|Melting]] | **[[Drifting#Melting|Melting]] | ||
** [[Drifting#Flowing|Flowing]] | **[[Drifting#Flowing|Flowing]] | ||
*[[External geometry]] | *[[External geometry]] | ||
*[[Perspective distortions]] | *[[Perspective distortions]] | ||
Line 78: | Line 78: | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[Geometry]]</h4> | <h4 class="media-heading">[[Geometry]]</h4> | ||
* [[Geometry#8A - Exposure to semantic concept network|8A - Exposure to semantic concept network]] | *[[Geometry#8A - Exposure to semantic concept network|8A - Exposure to semantic concept network]] | ||
* [[Geometry#8B - Perceived exposure to inner mechanics of consciousness|8B - Perceived exposure to inner mechanics of consciousness]] | *[[Geometry#8B - Perceived exposure to inner mechanics of consciousness|8B - Perceived exposure to inner mechanics of consciousness]] | ||
</li> | </li> | ||
Line 100: | Line 100: | ||
</div> | </div> | ||
<div class= | <div class="flex-column"> | ||
<div class="panel radius"> | <div class="panel radius"> | ||
<h3 class="panel-header">[[Cognitive effects - Psychedelics|Cognitive effects]] [[File:User.svg|x20px|right|link=]]</h3> | <h3 class="panel-header">[[Cognitive effects - Psychedelics|Cognitive effects]] [[File:User.svg|x20px|right|link=]]</h3> | ||
Line 127: | Line 127: | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">Suppressions</h4> | <h4 class="media-heading">Suppressions</h4> | ||
* [[Thought disorganization]] | *[[Thought disorganization]] | ||
* [[Personal bias suppression]] | *[[Personal bias suppression]] | ||
* [[Addiction suppression]]<ref>Psychedelics: entering a new age of addiction therapy | http://www.pharmaceutical-journal.com/news-and-analysis/features/psychedelics-entering-a-new-age-of-addiction-therapy/20066899.article#fn_link_1</ref> | *[[Addiction suppression]]<ref>Psychedelics: entering a new age of addiction therapy | http://www.pharmaceutical-journal.com/news-and-analysis/features/psychedelics-entering-a-new-age-of-addiction-therapy/20066899.article#fn_link_1</ref> | ||
* [[Memory suppression]] | *[[Memory suppression]] | ||
** [[Ego death]] | **[[Ego death]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">Alterations</h4> | <h4 class="media-heading">Alterations</h4> | ||
* [[Analysis enhancement]] | *[[Analysis enhancement]] | ||
* [[Conceptual thinking]] | *[[Conceptual thinking]] | ||
* [[Déjà vu]] | *[[Déjà vu]] | ||
* [[Delusion|Delusions]] | *[[Delusion|Delusions]] | ||
* [[Perceived exposure to inner mechanics of consciousness]] | *[[Perceived exposure to inner mechanics of consciousness]] | ||
* [[Introspection]] | *[[Introspection]] | ||
* [[Mindfulness]] | *[[Mindfulness]] | ||
* [[Outrospection]] | *[[Outrospection]] | ||
* [[Personality regression]] | *[[Personality regression]] | ||
* [[Simultaneous emotions]] | *[[Simultaneous emotions]] | ||
* [[Autonomous voice communication]] | *[[Autonomous voice communication]] | ||
* [[Thought loops]] | *[[Thought loops]] | ||
* [[Time distortion]] | *[[Time distortion]] | ||
</li> | </li> | ||
Line 167: | Line 167: | ||
</div> | </div> | ||
<div class= | <div class="flex-column"> | ||
<div class="panel radius"> | <div class="panel radius"> | ||
<h3 class="panel-header">Physical effects [[File:Child.svg|x20px|right|link=]]</h3> | <h3 class="panel-header">Physical effects [[File:Child.svg|x20px|right|link=]]</h3> | ||
Line 245: | Line 245: | ||
==Chemical classes== | ==Chemical classes== | ||
[[File:molecules.png|351px|thumb|right|''Psychedelic structural comparison diagram.]] | [[File:molecules.png|351px|thumb|right|''Psychedelic structural comparison diagram.'']] | ||
The "classical psychedelics" are all classed as [[Serotonergic psychedelic|serotonergic]] in nature.<ref name="nicholspsy" /> This means that they structurally mimic the endogenous [[neurotransmitter]] known as [[serotonin]], the neurotransmitter that regulates higher-level brain functions such as mood, sensory perception, cognition, and memory.<ref name="nichols5HT" /> | The "classical psychedelics" are all classed as [[Serotonergic psychedelic|serotonergic]] in nature.<ref name="nicholspsy" /> This means that they structurally mimic the endogenous [[neurotransmitter]] known as [[serotonin]], the neurotransmitter that regulates higher-level brain functions such as mood, sensory perception, cognition, and memory.<ref name="nichols5HT" /> | ||
Line 251: | Line 251: | ||
The three classes ([[phenethylamines]], [[lysergamides]] and [[tryptamines]]) all contain the same chemical rings (which have been labeled). | The three classes ([[phenethylamines]], [[lysergamides]] and [[tryptamines]]) all contain the same chemical rings (which have been labeled). | ||
* '''A''' represents the benzene ring, which all three classes contain. | *'''A''' represents the benzene ring, which all three classes contain. | ||
* '''B''' represents the pyrrole ring in both tryptamines and lysergamides. | *'''B''' represents the pyrrole ring in both tryptamines and lysergamides. | ||
* '''A''' and '''B''' together form the indole ring. | *'''A''' and '''B''' together form the indole ring. | ||
* '''C''' (cyclohexane) and '''D''' are only contained in the lysergamides, possibly contributing to their potency. | *'''C''' (cyclohexane) and '''D''' are only contained in the lysergamides, possibly contributing to their potency. | ||
===Examples=== | ===Examples=== | ||
<div class= | <div class="flex-panel"> | ||
<div class= | <div class="flex-column"> | ||
<div class="panel radius"> | <div class="panel radius"> | ||
<h3 class="panel-header">[[Lysergamides]][[File:book.svg|x20px|right|link=]]</h3> | <h3 class="panel-header">[[Lysergamides]][[File:book.svg|x20px|right|link=]]</h3> | ||
<ul class="featured-table"> | <ul class="featured-table"> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
* [[1B-LSD]] | *[[Talk:1cP-LSD|1cP-LSD]] | ||
* [[1P-ETH-LAD]] | *[[1B-LSD]] | ||
* [[1P-LSD]] | *[[1P-ETH-LAD]] | ||
* [[AL-LAD]] | *[[1P-LSD]] | ||
* [[ALD-52]] | *[[AL-LAD]] | ||
* [[ETH-LAD]] | *[[ALD-52]] | ||
* [[LSA]] | *[[ETH-LAD]] | ||
* [[LSD]] | *[[LSA]] | ||
* [[LSM-775]] | *[[LSD]] | ||
* [[LSZ]] | *[[LSM-775]] | ||
* [[MIPLA]] | *[[LSZ]] | ||
* [[PARGY-LAD]] | *[[MIPLA]] | ||
* [[PRO-LAD]] | *[[PARGY-LAD]] | ||
*[[PRO-LAD]] | |||
</li> | </li> | ||
</div> | </div> | ||
Line 288: | Line 289: | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[Base tryptamines]]</h4> | <h4 class="media-heading">[[Base tryptamines]]</h4> | ||
* [[DMT]] | *[[DMT]] | ||
* [[MET]] | *[[MET]] | ||
* [[DET]] | *[[DET]] | ||
* [[MPT]] | *[[MPT]] | ||
* [[EPT]] | *[[EPT]] | ||
* [[DPT]] | *[[DPT]] | ||
* [[DiPT]] | *[[DiPT]] | ||
* [[MiPT]] | *[[MiPT]] | ||
* [[EiPT]] | *[[EiPT]] | ||
* [[PiPT]] | *[[PiPT]] | ||
* [[aMT]] | *[[aMT]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[Substituted tryptamines]]</h4> | <h4 class="media-heading">[[Substituted tryptamines]]</h4> | ||
* [[4-AcO-DET]] (''Ethacetin'') | *[[4-AcO-DET]] (''Ethacetin'') | ||
* [[4-AcO-DMT]] (''Psilacetin'') | *[[4-AcO-DMT]] (''Psilacetin'') | ||
* [[4-AcO-DPT]] | *[[4-AcO-DPT]] | ||
* [[4-AcO-DiPT]] (''Ipracetin'') | *[[4-AcO-DiPT]] (''Ipracetin'') | ||
* [[4-AcO-EPT]] | *[[4-AcO-EPT]] | ||
* [[4-AcO-MET]] (''Metacetin'', ''Azomet'') | *[[4-AcO-MET]] (''Metacetin'', ''Azomet'') | ||
* [[4-AcO-MPT]] | *[[4-AcO-MPT]] | ||
* [[4-AcO-MiPT]] (''Mipracetin'') | *[[4-AcO-MiPT]] (''Mipracetin'') | ||
* [[4-HO-DET]] (''Ethocin'') | *[[4-HO-DET]] (''Ethocin'') | ||
* [[4-HO-DMT]] (''Psilocin'') | *[[4-HO-DMT]] (''Psilocin'') | ||
* [[4-HO-DPT]] | *[[4-HO-DPT]] | ||
* [[4-HO-DiPT]] (''Iprocin'') | *[[4-HO-DiPT]] (''Iprocin'') | ||
* [[4-HO-EPT]] | *[[4-HO-EPT]] | ||
* [[4-HO-MET]] (''Metocin'') | *[[4-HO-MET]] (''Metocin'') | ||
* [[4-HO-MPT]] | *[[4-HO-MPT]] | ||
* [[4-HO-MiPT]] (''Miprocin'') | *[[4-HO-MiPT]] (''Miprocin'') | ||
* [[4-PO-DMT]] (''Psilocybin'') | *[[4-PO-DMT]] (''Psilocybin'') | ||
* [[5-HO-DMT]] (''Bufotenin'') | *[[5-HO-DMT]] (''Bufotenin'') | ||
* [[5-MeO-DALT]] | *[[5-MeO-DALT]] | ||
* [[5-MeO-DMT]] | *[[5-MeO-DMT]] | ||
* [[5-MeO-DiPT]] (''Foxy'') | *[[5-MeO-DiPT]] (''Foxy'') | ||
* [[5-MeO-MALT]] | *[[5-MeO-MALT]] | ||
* [[5-MeO-MiPT]] (''Moxy'') | *[[5-MeO-MiPT]] (''Moxy'') | ||
* [[Ibogaine]] | *[[Ibogaine]] | ||
</li> | </li> | ||
</div> | </div> | ||
</div> | </div> | ||
<div class= | <div class="flex-column"> | ||
<div class="panel radius"> | <div class="panel radius"> | ||
<h3 class="panel-header">[[Phenethylamines]] [[File:flask.svg|x20px|right|link=]]</h3> | <h3 class="panel-header">[[Phenethylamines]] [[File:flask.svg|x20px|right|link=]]</h3> | ||
<ul class="featured-table"> | <ul class="featured-table"> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
* [[Allylescaline]] | *[[Allylescaline]] | ||
* [[Escaline]] | *[[Escaline]] | ||
* [[Mescaline]] | *[[Mescaline]] | ||
* [[Methallylescaline]] | *[[Methallylescaline]] | ||
* [[Proscaline]] | *[[Proscaline]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[2C-x]] series</h4> | <h4 class="media-heading">[[2C-x]] series</h4> | ||
* [[2C-B]] | *[[2C-B]] | ||
* [[2C-C]] | *[[2C-C]] | ||
* [[2C-D]] | *[[2C-D]] | ||
* [[2C-E]] | *[[2C-E]] | ||
* [[2C-H]] | *[[2C-H]] | ||
* [[2C-I]] | *[[2C-I]] | ||
* [[2C-P]] | *[[2C-P]] | ||
* [[2C-TFM]] | *[[2C-TFM]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[2C-T-x]] series</h4> | <h4 class="media-heading">[[2C-T-x]] series</h4> | ||
* [[2C-T]] | *[[2C-T]] | ||
* [[2C-T-2]] | *[[2C-T-2]] | ||
* [[2C-T-21]] | *[[2C-T-21]] | ||
* [[2C-T-7]] | *[[2C-T-7]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[DOx]] series</h4> | <h4 class="media-heading">[[DOx]] series</h4> | ||
* [[DOB]] | *[[DOB]] | ||
* [[DOC]] | *[[DOC]] | ||
* [[DOET]] (''DOE'') | *[[DOET]] (''DOE'') | ||
* [[DOI]] | *[[DOI]] | ||
* [[DOM]] | *[[DOM]] | ||
* [[DOPR]] | *[[DOPR]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[25x-NBOMe]] series</h4> | <h4 class="media-heading">[[25x-NBOMe]] series</h4> | ||
* [[25B-NBOMe]] | *[[25B-NBOMe]] | ||
* [[25C-NBOMe]] | *[[25C-NBOMe]] | ||
* [[25D-NBOMe]] | *[[25D-NBOMe]] | ||
* [[25I-NBOMe]] | *[[25I-NBOMe]] | ||
* [[25N-NBOMe]] | *[[25N-NBOMe]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">[[25x-NBOH]] series</h4> | <h4 class="media-heading">[[25x-NBOH]] series</h4> | ||
* [[25B-NBOH]] | *[[25B-NBOH]] | ||
* [[25C-NBOH]] | *[[25C-NBOH]] | ||
* [[25I-NBOH]] | *[[25I-NBOH]] | ||
</li> | </li> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
<h4 class="media-heading">Others</h4> | <h4 class="media-heading">Others</h4> | ||
* [[3C-E]] | *[[3C-E]] | ||
* [[ßk-2C-B]] | *[[ßk-2C-B]] | ||
* [[TMA-2]] | *[[TMA-2]] | ||
* [[TMA-6]] | *[[TMA-6]] | ||
</li> | </li> | ||
</div> | </div> | ||
Line 403: | Line 404: | ||
<ul class="featured-table"> | <ul class="featured-table"> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
* [[2C-B-FLY]] | *[[2C-B-FLY]] | ||
* [[5-MeO-DiBF]] | *[[5-MeO-DiBF]] | ||
* [[Bromo-DragonFLY]] | *[[Bromo-DragonFLY]] | ||
</li> | </li> | ||
</div> | </div> | ||
</div> | </div> | ||
<div class= | <div class="flex-column"> | ||
<div class="panel radius"> | <div class="panel radius"> | ||
<h3 class="panel-header">[[Entheogens]] [[File:users.svg|x20px|right|link=]]</h3> | <h3 class="panel-header">[[Entheogens]] [[File:users.svg|x20px|right|link=]]</h3> | ||
<ul class="featured-table"> | <ul class="featured-table"> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
* [[Acacia confusa]] | *[[Acacia confusa]] | ||
* [[Ayahuasca]] | *[[Ayahuasca]] | ||
* [[Chacruna]] | *[[Chacruna]] | ||
* [[Hawaiian baby woodrose]] | *[[Hawaiian baby woodrose]] | ||
* [[Iboga]] | *[[Iboga]] | ||
* [[Mimosa hostilis]] | *[[Mimosa hostilis]] | ||
* [[Morning glory]] | *[[Morning glory]] | ||
* [[Psilocybin mushrooms]] | *[[Psilocybin mushrooms]] | ||
* [[Psychedelic cacti]] | *[[Psychedelic cacti]] | ||
* [[Yopo]] | *[[Yopo]] | ||
</li> | </li> | ||
</div> | </div> | ||
Line 432: | Line 433: | ||
<ul class="featured-table"> | <ul class="featured-table"> | ||
<li class="featured list-item"> | <li class="featured list-item"> | ||
* [[Efavirenz]] | *[[Efavirenz]] | ||
</li> | </li> | ||
</ul> | </ul> | ||
Line 466: | Line 467: | ||
==See also== | ==See also== | ||
* [[Responsible use]] | |||
* [[Hallucinogen]] | *[[Responsible use]] | ||
* [[Dissociative]] | *[[Hallucinogen]] | ||
* [[Deliriant]] | *[[Dissociative]] | ||
* [[Serotonin]] | *[[Deliriant]] | ||
*[[Serotonin]] | |||
==External links== | ==External links== | ||
* [https://en.wikipedia.org/wiki/Psychedelics Psychedelics (Wikipedia)] | |||
*[https://en.wikipedia.org/wiki/Psychedelics Psychedelics (Wikipedia)] | |||
==Literature== | ==Literature== | ||
* Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478 | |||
* Geyer, M. A., Nichols, D. E., & Vollenweider, F. X. (2009). Serotonin-Related Psychedelic Drugs. Encyclopedia of Neuroscience. https://doi.org/10.1016/b978-008045046-9.01160-8 | *Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478 | ||
*Geyer, M. A., Nichols, D. E., & Vollenweider, F. X. (2009). Serotonin-Related Psychedelic Drugs. Encyclopedia of Neuroscience. https://doi.org/10.1016/b978-008045046-9.01160-8 | |||
*Preller, K. H., & Vollenweider, F. X. (2016). Phenomenology, Structure, and Dynamic of Psychedelic States. https://doi.org/10.1007/7854_2016_459 | *Preller, K. H., & Vollenweider, F. X. (2016). Phenomenology, Structure, and Dynamic of Psychedelic States. https://doi.org/10.1007/7854_2016_459 | ||
* Vollenweider, F. X., & Kometer, M. (2010). The Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders. Nature Publishing Group, 11(9), 642–651. https://doi.org/10.1038/nrn2884 | *Vollenweider, F. X., & Kometer, M. (2010). The Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders. Nature Publishing Group, 11(9), 642–651. https://doi.org/10.1038/nrn2884 | ||
*Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. https://doi.org/10.1038/npp.2017.84 | *Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. https://doi.org/10.1038/npp.2017.84 | ||
* Nichols, C. D., & Sanders-Bush, E. (2001). Serotonin Receptor Signaling and Hallucinogenic Drug Action. Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf | *Nichols, C. D., & Sanders-Bush, E. (2001). Serotonin Receptor Signaling and Hallucinogenic Drug Action. Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf | ||
* Johansen, P. Ø., & Krebs, T. S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology, 29(3), 270-279. https://doi.org/10.1177/0269881114568039 | *Johansen, P. Ø., & Krebs, T. S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology, 29(3), 270-279. https://doi.org/10.1177/0269881114568039 | ||
* Elsey, J. W. (2017). Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy. Drug Science, Policy and Law, 3, 2050324517723232. https://doi.org/10.1177/2050324517723232 | *Elsey, J. W. (2017). Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy. Drug Science, Policy and Law, 3, 2050324517723232. https://doi.org/10.1177/2050324517723232 | ||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Psychoactive class]][[Category:Hallucinogen]][[Category:Psychedelic|*]] | [[Category:Psychoactive class]] | ||
[[Category:Hallucinogen]] | |||
[[Category:Psychedelic|*]] |